Allergan’s new VEGF inhibitor may reduce injection burden for wet AMD

Findings from 2 late-stage trials hint that abicipar pegol performs on par with ranibizumab for neovascular AMD, but requires half the injections.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553